Navigation Links
Children's Hospitals and Clinics of Minnesota Receive Level III Trauma Designation
Date:7/27/2009

MINNEAPOLIS and ST. PAUL, Minn., July 27 /PRNewswire/ -- The Minnesota Department of Health recently designated Children's Hospitals and Clinics of Minnesota's two hospital locations as Level III Trauma Hospitals. Children's of Minnesota has the sixth busiest pediatric emergency department in the nation with over 84,000 visits per year, and already treats around 450 trauma cases each year. Children's voluntarily participated in the intense designation process, which included an external review of the hospitals' resources and capabilities to care for young trauma patients. Children's met the required standards of commitment, clinical and equipment resources, and staff training.

Children's President and CEO Alan L. Goldbloom, MD, said Children's of Minnesota is proud to achieve this designation, and is working toward higher trauma level designation down the road.

"Trauma care is one of the most important services we provide," said Goldbloom. "Studies show that children who suffer trauma do best when treated at children's hospitals. This designation will help us deliver that care even more effectively to more families. We have also begun the process of developing the capabilities to be certified as a Level I pediatric trauma center at Children's, as part of our continuing effort to bring the best quality of care to all children and families in Minnesota."

For a severely injured person, the time between sustaining an injury and receiving definitive care is the most important predictor of survival. The Level III Trauma designation for Children's means children who are severely injured will have a better chance of being able to get the critical care they need in a timely manner.

"Trauma is the third leading cause of death in Minnesota," said Minnesota Commissioner of Health, Dr. Sanne Magnan. "The goal of the trauma system is to decrease injured pati
'/>"/>

SOURCE Children's Hospitals and Clinics of Minnesota
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. 200 Families of Children With Serious Eye Problems Benefit From Unique Gift Card Program at The Vision Center at Childrens Hospital Los Angeles
2. Childrens Bedding Naturally Enhances Emotional Well-being
3. Cydcor Builds Bears and Bonds in Special Charity Event Benefitting Childrens Hospital Los Angeles
4. National Childrens Study Begins Recruiting
5. Jessica Biel and Make The Difference Network Bring Holiday Cheer to Childrens Hospital Los Angeles
6. Siegel+Gale Designs New HOPE Portal for Childrens Hospital Los Angeles
7. Childrens Hospital Los Angeles Turns Off the Tap With Green Earth Waterless Carwash
8. Nautica Malibu Triathlon Presented by Toyota Raises $718,000 for Childrens Hospital Los Angeles Pediatric Cancer Research
9. SEIU Security Officers Who Protect Kaiser Permanente Hospitals Nationwide Vote Overwhelmingly to Ratify First-Ever Union Contract
10. Health Care Without Harm Partners With Clinton Climate Initiative to Help Hospitals and Healthcare Facilities Reduce Environmental Impact
11. Nine CareTech Solutions Client-Hospitals Named 2009 Most Wired Winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 01, 2015 “ The Barrel Mill ” ... Report, which takes a look at the latest and coolest ... host of NewsWatch and a technology expert, conducted the review ... flavor to drinks. , According to Home Distillation of Alcohol, ... spirits. Well, there’s a pretty cool product that’ll help anyone ...
(Date:2/28/2015)... March 01, 2015 Heart diseases are ... 10 percent of urban adult population and 5 percent ... heart diseases and 20-30 percent of them require specialized ... ailments and coronary vascular diseases (CVD). , A division ... new market research report titled “Indian Coronary Stent Market ...
(Date:2/28/2015)... February 28, 2015 The Classic ... offering a new special. Throughout all of March ... , This service can help overall ... and pain. Patients may notice certain symptoms that suggest ... These symptoms include: , 1.    Pain, clicking, and popping ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
Breaking Medicine News(10 mins):Health News:An Oak Infusion Spiral was Featured on NewsWatch Television on January 30, 2015 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2
... properties blocked bacteria formation, delayed onset of ... (HealthDay News) -- The use of silver-coated ... among intensive-care patients on ventilators, a U.S. ... lead to longer hospital stays, increased costs, ...
... In fact, new study hints they might be hazardous , , ... whether folic acid and vitamin B supplements help the heart ... any good and might have even caused participants harm. , ... -- no benefit of taking vitamin B supplements to reduce ...
... DIEGO, Aug. 19 NuVasive, Inc. (Nasdaq:,NUVA), a ... disruptive surgical treatments for the spine, announced today,that ... Sofamor Danek,alleging patent infringement involving certain NuVasive products., ... "It is not surprising,that Medtronic would attempt to ...
... India and BALTIMORE, Aug. 19 Lupin Ltd.,announced today ... marketing agreement for the AeroChamber Plus(R) line of products ... Lupin,Pharmaceuticals, Inc., USA, will use its 50 person sales ... is a Valved Holding Chamber (VHC) device that is,used ...
... COO, Former Experian Executive Will Lead Private Access, Mission to ... privacy management and ... clinical trials recruitment tools, ALISO VIEJO, Calif., Aug. ... enable management of detailed,privacy preferences for personal health information, announced ...
... MD, August 18, 2008Young researchers presented innovative, early-stage ... a collaborative project of the AUA Foundation and ... August 7-9, 2008. The AUA Foundation hosted the ... the most cutting-edge research in sexual medicine. ...
Cached Medicine News:Health News:Silver-Coated Ventilator Tubes Cut Risk of Pneumonia 2Health News:Vitamin B, Folate Supplements Won't Help Heart 2Health News:Vitamin B, Folate Supplements Won't Help Heart 3Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 2Health News:NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek 3Health News:Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 2Health News:VirtualHealth Technologies, Inc., Announces Its Associate, Private Access, Appoints Marc Kirshbaum as President & COO 3Health News:New research on sexual function 2
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
(Date:2/27/2015)... , Feb. 27, 2015   Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... (NORD™), the European Organisation for Rare Diseases™ (EURORDIS™), ... world in observing Rare Disease Day. ... patient organizations, industry, and other participants conduct special ...
Breaking Medicine Technology:Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... Nov. 22, 2011 Cardica, Inc. (Nasdaq: CRDC ... under its distribution agreement and loan commitment with Century Medical. ... the $4 million loan commitment from Century. Under the terms ... balance of all amounts drawn by Cardica will be due ...
... 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... and Drug Administration (FDA) has accepted for review the ... for Subcutaneous Use for the prevention of gout flares ... Drug User Fee Act (PDUFA), the goal for a ...
Cached Medicine Technology:Cardica Achieves Second Milestone Under Century Distribution Agreement 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8
Angled for temporal approach. Solid 14 mm blades. Dull finish....
Open 11 mm blades. Polished finish....
Open 10 mm blades. Dull finish....
Angled for temporal approach. Open 14 mm rounded blades for patient comfort. Dull finish....
Medicine Products: